TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Research  »  Epilepsy Research Web  » 

Skip secondary menu

Epilepsy Benchmark IB2

Research @ NINDS
Judith Hoyer Lecture on Epilepsy

Curing the Epilepsies 2013: Pathways Forward

Resource Links
Anticonvulsant Screening Program (ASP)

NIH RePORTER is an electronic tool that allows users to search a repository of NIH-funded research projects and access publications and patents resulting from NIH funding.

Epilepsy Clinical Trials

Resources for Scientists


Brandy Fureman, Ph.D.
Program Director, Channels Synapses & Circuits Cluster

Deborah Hirtz, M.D.
Program Director, Division of Extramural Research

John Kehne, Ph.D.
Program Director, Anticonvulsant Screening Program

Randall Stewart, Ph.D.
Program Director, Extramural Research Program

Vicky Whittemore, Ph.D.
Program Director, Channels, Synapses & Neural Circuits Cluster


Epilepsy Benchmark IB2

Benchmark Area I: Understanding basic mechanisms of epileptogenesis

Section B: Continue the progress of identifying the genes predisposing to epilepsy

Specific Benchmark 2: Create a national consortium aimed at identifying new epilepsy susceptibility genes through a large-scale genotype:phenotype screen. Initiate this effort with a consensus conference that prioritizes phenotypes, develops implementation strategies, and defines endpoints.

2005 Report submitted by Benchmark Steward(s):
Ruth Ottman, Ph.D. (Columbia University)

Background of the benchmark goal:   
Most epilepsy is not consistent with Mendelian modes of inheritance.  The genes that influence risk in the majority of patients are likely to have small effects, interacting with the effects of environmental factors.  Identification of such genes requires very large numbers of patients.  Thus a collaborative study, with the highest quality of methods for phenotype and genotype analysis, is essential to move the field forward.

Current status of field:
Allelic association studies are being performed by many separate groups, and published at a rapidly increasing rate.  Most of these studies are underpowered.  Consequently, about half of the reported findings are positive, and half negative, and no association has been consistently confirmed. 

Activities update: 
Dan Lowenstein spearheaded a multi-institutional effort to conduct a state-of-the-art study of genes in genetically complex epilepsies.  The result was a collaboration of 14 institutions throughout the U.S., and a well-designed, adequately powered study to address the most pressing issues in epilepsy genetics (e.g., gene discovery in genetically complex epilepsies, genes influencing treatment response, and the role of somatic mutations).  The proposal for this project, which will include 5,000 superbly well-characterized patients and 15,000 controls, was submitted to NIH for review.

Top priorities for next 5-10 years:

  • Identification of genetic polymorphisms that influence risk for genetically complex epilepsies and for response to treatments.
  • Development and evaluation of methods to use genetic information to develop new treatments and tailor them to specific patients.
  • Development of new paradigms for epilepsy classification that reflect shared and distinct genetic mechanisms.

Roadblocks to progress:
Study designs involving large numbers of patients, with state-of-the-art genomic analysis and clinical characterization, are extremely expensive.


  1. Bergmann C, Zerres K, Senderek J, et al. Oligophrenin 1 (OPHN1) gene mutation causes syndromic X-linked mental retardation with epilepsy, rostral ventricular enlargement and cerebellar hypoplasia. Brain 2003;126:1537-1544.
  2. Berkovic SF, Izzillo P, McMahon JM, et al. LGI1 mutations in temporal lobe epilepsies. Neurology 2004;62:1115-1119.
  3. Berkovic SF, Serratosa JM, Phillips HA, et al. Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12. Epilepsia 2004;45:1054-1060.
  4. Chan EM, Bulman DE, Paterson AD, et al. Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet 2003;40:671-675.
  5. Chan EM, Young EJ, Ianzano L, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 2003;35:125-127.
  6. Cho YW, Motamedi GK, Laufenberg I, et al. A Korean kindred with autosomal dominant nocturnal frontal lobe epilepsy and mental retardation. Arch Neurol 2003;60:1625-1632.
  7. Claes L, Ceulemans B, Audenaert D, et al. De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy. Hum Mutat 2003;21:615-621.
  8. Combi R, Dalpra L, Malcovati M, Oldani A, Tenchini ML, Ferini-Strambi L. Evidence for a fourth locus for autosomal dominant nocturnal frontal lobe epilepsy. Brain Res Bull 2004;63:353-359.
  9. Coppola G, Castaldo P, Miraglia del Giudice E, et al. A novel KCNQ2 K+ channel mutation in benign neonatal convulsions and centrotemporal spikes. Neurology 2003;61:131-134.
  10. de Falco FA, Striano P, de Falco A, et al. Benign adult familial myoclonic epilepsy: genetic heterogeneity and allelism with ADCME. Neurology 2003;60:1381-1385.
  11. Dedek K, Fusco L, Teloy N, Steinlein OK. Neonatal convulsions and epileptic encephalopathy in an Italian family with a missense mutation in the fifth transmembrane region of KCNQ2. Epilepsy Res 2003;54:21-27.
  12. Fertig E, Lincoln A, Martinuzzi A, Mattson RH, Hisama FM. Novel LGI1 mutation in a family with autosomal dominant partial epilepsy with auditory features. Neurology 2003;60:1687-1690.
  13. Foncke EM, Klein C, Koelman JH, et al. Hereditary myoclonus-dystonia associated with epilepsy. Neurology 2003;60:1988-1990.
  14. Fujiwara T, Sugawara T, Mazaki-Miyazaki E, et al. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 2003;126:531-546.
  15. Fukuma G, Oguni H, Shirasaka Y, et al. Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia 2004;45:140-148.
  16. Greenberg DA, Cayanis E, Strug L, et al. Malic enzyme 2 may underlie susceptibility to adolescent-onset idiopathic generalized epilepsy. Am J Hum Genet 2005;76:139-146.
  17. Gu W, Brodtkorb E, Steinlein OK. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol 2002;52:364-367.
  18. Gu W, Sander T, Becker T, Steinlein OK. Genotypic association of exonic LGI4 polymorphisms and childhood absence epilepsy. Neurogenetics 2004;5:41-44.
  19. Guerrini R, Moro F, Andermann E, et al. Nonsyndromic mental retardation and cryptogenic epilepsy in women with doublecortin gene mutations. Ann Neurol 2003;54:30-37.
  20. Guerrini R, Parmeggiani L, Marini C, Brovedani P, Bonanni P. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with linkage to chromosome 2p11.1-q12.2. Adv Neurol 2005;95:273-279.
  21. Haug K, Warnstedt M, Alekov AK, et al. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet 2003;33:527-532.
  22. Kamiya K, Kaneda M, Sugawara T, et al. A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline. J Neurosci 2004;24:2690-2698.
  23. Leniger T, Kananura C, Hufnagel A, Bertrand S, Bertrand D, Steinlein OK. A new Chrna4 mutation with low penetrance in nocturnal frontal lobe epilepsy. Epilepsia 2003;44:981-985.
  24. Leppert MF, Singh NA. Nonsyndromic seizure disorders: epilepsy and the use of the internet to advance research. Annu Rev Genomics Hum Genet 2003;4:437-457.
  25. Lossin C, Rhodes TH, Desai RR, et al. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci 2003;23:11289-11295.
  26. Marini C, Harkin LA, Wallace RH, Mulley JC, Scheffer IE, Berkovic SF. Childhood absence epilepsy and febrile seizures: a family with a GABA(A) receptor mutation. Brain 2003;126:230-240.
  27. McLellan A, Phillips HA, Rittey C, et al. Phenotypic comparison of two Scottish families with mutations in different genes causing autosomal dominant nocturnal frontal lobe epilepsy. Epilepsia 2003;44:613-617.
  28. Michelucci R, Poza JJ, Sofia V, et al. Autosomal dominant lateral temporal epilepsy: clinical spectrum, new epitempin mutations, and genetic heterogeneity in seven European families. Epilepsia 2003;44:1289-1297.
  29. Moulard B, Darcel F, Mignard D, et al. FOunder effect in patients with Unverricht-Lundborg disease on reunion island. Epilepsia 2003;44:1357-1360.
  30. Nabbout R, Gennaro E, Dalla Bernardina B, et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology 2003;60:1961-1967.
  31. Nakayama J, Hamano K, Iwasaki N, et al. Mutation analysis of the leucine-rich, glioma inactivated 1 gene (LGI1) in Japanese febrile seizure patients. Neuropediatrics 2003;34:234-236.
  32. Noebels JL. The biology of epilepsy genes. Annu Rev Neurosci 2003;26:599-625.
  33. Ottman R, Winawer MR, Kalachikov S, et al. LGI1 mutations in autosomal dominant partial epilepsy with auditory features. Neurology 2004;62:1120-1126.
  34. Pal DK, Evgrafov OV, Tabares P, Zhang F, Durner M, Greenberg DA. BRD2 (RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy. Am J Hum Genet 2003;73:261-270.
  35. Patterson EE, Mickelson JR, Da Y, et al. Clinical characteristics and inheritance of idiopathic epilepsy in Vizslas. J Vet Intern Med 2003;17:319-325.
  36. Pizzuti A, Flex E, Di Bonaventura C, et al. Epilepsy with auditory features: a LGI1 gene mutation suggests a loss-of-function mechanism. Ann Neurol 2003;53:396-399.
  37. Ranta S, Topcu M, Tegelberg S, et al. Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy. Hum Mutat 2004;23:300-305.
  38. Rozycka A, Skorupska E, Kostyrko A, Trzeciak WH. Evidence for S284L mutation of the CHRNA4 in a white family with autosomal dominant nocturnal frontal lobe epilepsy. Epilepsia 2003;44:1113-1117.
  39. Saez-Hernandez L, Peral B, Sanz R, et al. Characterization of a 6p21 translocation breakpoint in a family with idiopathic generalized epilepsy. Epilepsy Res 2003;56:155-163.
  40. Sander T, Windemuth C, Schulz H, et al. Exploration of a putative susceptibility locus for idiopathic generalized epilepsy on chromosome 8p12. Epilepsia 2003;44:32-39.
  41. Sheen VL, Topcu M, Berkovic S, et al. Autosomal recessive form of periventricular heterotopia. Neurology 2003;60:1108-1112.
  42. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-1448.
  43. Simpson MA, Cross H, Proukakis C, et al. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet 2004;36:1225-1229.
  44. Suzuki T, Delgado-Escueta AV, Aguan K, et al. Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet 2004;36:842-849.
  45. Tan NC, Mulley JC, Berkovic SF. Genetic association studies in epilepsy: "the truth is out there". Epilepsia 2004;45:1429-1442.
  46. Weale ME, Depondt C, Macdonald SJ, et al. Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am J Hum Genet 2003;73:551-565.

Last Modified October 20, 2015